PERIOLIMEL / OLIMEL

PERIOLIMEL N4E, emulsion for infusion
OLIMEL N5E, emulsion for infusion
OLIMEL N7E, emulsion for infusion
OLIMEL N9E, emulsion for infusion
OLIMEL N7, emulsion for infusion
OLIMEL N9, emulsion for infusion

COMPOSITION

For PERIOLIMEL N4E, OLIMEL N5E, OLIMEL N7E and OLIMEL N9E:
Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Sodium acetate, trihydrate; Sodium glycerophosphate, hydrated; Potassium chloride; Magnesium chloride, hexahydrate; Calcium chloride, dehydrate; Glucose anhydrous

For OLIMEL N7 and OLIMEL N9:

Active substances: Refined olive oil + refined soybean oil; Alanine; Arginine; Aspartic acid; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Glucose anhydrous

Therapeutic indications
PERIOLIMEL / OLIMEL are indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

PERIOLIMEL / OLIMEL are not recommended for use in children less than 2 years of age due to inadequate composition and volume.

Contraindications
The use of PERIOLIMEL / OLIMEL are contra-indicated in the following situations:
- In premature neonates, infants and children less than 2 years of age
- Hypersensitivity to egg, soybean, or peanut proteins, or to any of the active substances or excipients
- Congenital abnormalities of amino acid metabolism
- Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia
- Severe hyperglycemia
- Pathologically-elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.

Undesirable effects

		Frequency[a]
	Tachycardia	Common
	Anorexia	Common
	Hypertriglyceridemia	Common
	Abdominal pain	Common
	Diarrhea	Common
	Nausea	Common
	Hypertension	Common

The following class-like-adverse drug reactions (ADRs) have been described in other sources in relation to similar parenteral nutrition products; the frequency of these events is not known.

- Blood and Lymphatic System Disorders: Thrombocytopenia
- Hepatobiliary Disorders: Cholestasis, Hepatomegaly, Jaundice
- Immune System Disorders: Hypersensitivity
- Investigations: Blood alkaline phosphatase increased, Transaminases increased, Blood bilirubin increased, Elevated liver enzymes
- Renal and Urinary Disorders: Azotemia
- Vascular disorders: Pulmonary vascular precipitates (pulmonary vascular embolism and respiratory distress)

Fat overload syndrome (very rare)

For a detailed posology, Special warnings and precautions, incompatibilities, interactions, pharmacological properties and pharmaceutical particulars, please refer to the full SPC.

Medicinal products are subject to medical prescription. Revision date: June 2018